COVID-19 Vaccine Janssen: Guillain-Barr é syndrome (GBS) listed as a very rare side effect, EMA
The European PRAC has assessed the available information (108 cases reported worldwide, when over 21 million had received the vaccine) and concluded that a causal relationship between Covid-19 Vaccine Janssen and the neurological disorder GBS is possible. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - July 26, 2021 Category: Consumer Health News Source Type: news

JJ vaccine may cause Guillain-Barré Syndrome, warns FDA
(Natural News) The Food and Drug Administration (FDA) states that Guillain-Barré Syndrome (GBS) is a potential adverse effect of the Johnson & Johnson COVID-19 vaccine. According to the agency, there have been 100 reports of the rare but serious neurological disorder, following vaccination with said vaccine as of July 13. GBS causes inflammation of the nerves which can lead to... (Source: NaturalNews.com)
Source: NaturalNews.com - July 25, 2021 Category: Consumer Health News Source Type: news

CDC Panel Updates Info on Rare Side Effect After J & J Vaccine CDC Panel Updates Info on Rare Side Effect After J & J Vaccine
The ACIP discussed slightly higher rates of the rare side effect of Guillain-Barr é syndrome after the J&J vaccine, and presented reaffirming evidence of the vaccine's effectiveness against variants.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - July 23, 2021 Category: Drugs & Pharmacology Tags: Infectious Diseases News Source Type: news

J & J vaccine and Guillain-Barr é syndrome: Information on the FDA warning
Regulators and Yale experts say the benefits of receiving the vaccine still outweigh the risks, citing the rare chance of developing the neurological disorder. (Source: Yale Science and Health News)
Source: Yale Science and Health News - July 21, 2021 Category: Universities & Medical Training Source Type: news

What You Need to Know About COVID-19 Booster Shots
Since the U.S. began a massive country-wide vaccination effort against COVID-19 last winter, a majority of adult Americans have been immunized. But now it seems that all of them may need an additional dose next year. Public health experts including Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, stress that studies continue to show that the three vaccines currently authorized in the U.S. protect against COVID-19 disease, including against variants of the virus that are more transmissible. But as effective as the vaccines are, they can’t provide 100% immunity against disease. ...
Source: TIME: Health - July 15, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

Johnson & Johnson Single-Shot COVID-19 Vaccine Demonstrated a Durable Immune Response and Elicited Dual Mechanisms of Protection Against Delta and Other SARS-CoV-2 Variants of Concern in Data Published in New England Journal of Medicine
NEW BRUNSWICK, N.J., July 14, 2021 – Interim results from a Phase 1/2a sub-study published in the New England Journal of Medicine (NEJM) demonstrated that both humoral (antibody) and cellular (T-cell) immune responses generated by the Johnson & Johnson single-shot COVID-19 vaccine were strong and stable through eight months after immunization, the length of time evaluated to date. Data showed that T-cell responses – including the important CD8+ T-cells that seek out and destroy infected cells – persisted over the eight-month timeframe examined. The Company announced topline preprint study results from...
Source: Johnson and Johnson - July 14, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 5-8 July 2021, EMA
The PRAC has recommended a change to the product information for Vaxzevria (formerly COVID 19 Vaccine Astrazeneca) to include a warning to raise awareness among healthcare professionals and people taking the vaccine of cases of Guillain-Barre syndrome (GBS) reported following vaccination. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - July 14, 2021 Category: Consumer Health News Source Type: news

FDA Warns J & J Vaccine Can Increase Guillain-Barre
FDA to Warn J&J Vaccine Can Increase Guillain-Barre Risk (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - July 14, 2021 Category: General Medicine Source Type: news

FDA Warns About J & J COVID Vaccine and Guillain-Barr é Syndrome Risk
The first symptom of the disorder is usually a weakness or tingling sensation in both legs. (Source: Reuters: Health)
Source: Reuters: Health - July 13, 2021 Category: Consumer Health News Source Type: news

What is Guillain-Barré syndrome? FDA warns of ‘Increased risk’ after vaccine
GUILLAIN-BARR É syndrome has been linked to the Covid vaccine after US authorities warned the Johnson& Johnson jab may be related to the rare syndrome. But what is Guillain-Barr é syndrome? (Source: Daily Express - Health)
Source: Daily Express - Health - July 13, 2021 Category: Consumer Health News Source Type: news

The FDA ’s New Guillain-Barre Warning For the J & J Vaccine Reflects a Small Increased Risk of the Illness
As millions of people get vaccinated against COVID-19, the U.S. Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) are closely monitoring reports of side effects and adverse events among people getting immunized. On July 12, the FDA added a warning about the risk of Guillain-Barre to the single-dose Janssen/Johnson & Johnson vaccine. Anyone who receives the shot moving forward will get an updated fact sheet informing them of the small but increased risk. There have not been significant reports of the syndrome linked to the two other vaccines authorized in the U.S., made by Pfize...
Source: TIME: Health - July 13, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

FDA adds warning to J & J COVID-19 vaccine over links to rare autoimmune disorder
The U.S. Food and Drug Administration announced a new warning for the Johnson& Johnson COVID-19 vaccine over its association with an increased risk of Guillain-Barre syndrome. (Source: Health News - UPI.com)
Source: Health News - UPI.com - July 13, 2021 Category: Consumer Health News Source Type: news

Guillain-Barr é Syndrome and the Johnson & Johnson Vaccine: What to Know
The link between the rare neurological disorder and the Johnson& Johnson Covid-19 vaccine may be real, but the risk appears to be very small. (Source: NYT Health)
Source: NYT Health - July 13, 2021 Category: Consumer Health News Authors: Emily Anthes Tags: Vaccination and Immunization Coronavirus (2019-nCoV) Guillain-Barre Syndrome Centers for Disease Control and Prevention Food and Drug Administration Johnson & your-feed-health your-feed-science Source Type: news

FDA to Warn J & J Vaccine Can Increase Guillain-Barr é Risk: Media FDA to Warn J & J Vaccine Can Increase Guillain-Barr é Risk: Media
The federal agency is acting after receiving more than 100 reports of rare Guillain-Barr é syndrome linked to receipt of the J&J vaccines.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - July 13, 2021 Category: Drugs & Pharmacology Tags: Infectious Diseases News Source Type: news

F.D.A. Attaches Warning of Rare Nerve Syndrome to Johnson & Johnson Covid Vaccine
Federal regulators concluded that the risk of developing the syndrome was low, and that the benefits of the vaccine still strongly outweigh it. (Source: NYT Health)
Source: NYT Health - July 13, 2021 Category: Consumer Health News Authors: Sharon LaFraniere and Noah Weiland Tags: Johnson & Guillain-Barre Syndrome Vaccination and Immunization Drugs (Pharmaceuticals) Coronavirus (2019-nCoV) Disease Rates Regulation and Deregulation of Industry Food and Drug Administration Centers for Disease Control and Prevention Source Type: news

FDA Adds Guillain-Barr é Warning to J & J COVID-19 Vaccine
MONDAY, July 12, 2021 -- The U.S. Food and Drug Administration issued a new warning for the Johnson& Johnson COVID-19 vaccine that says the shot has been tied to Guillain-Barr é syndrome. Officials said there is a " small possible risk " for the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 12, 2021 Category: Pharmaceuticals Source Type: news

FDA adds new warning on Johnson & Johnson vaccine related to rare autoimmune disorder
About 100 preliminary reports of Guillain-Barré have been detected after 12.8 million doses of Johnson & Johnson vaccine were administered, the Centers for Disease Control and Prevention said in a statement. (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - July 12, 2021 Category: Consumer Health News Authors: Laurie McGinley Source Type: news

What To Know About The J&J COVID Vaccine And Guillain-Barre Syndrome
The FDA added a warning on the J&J shot after some people developed a rare disorder. Here's why you shouldn't panic. (Source: Healthy Living - The Huffington Post)
Source: Healthy Living - The Huffington Post - July 12, 2021 Category: Consumer Health News Source Type: news

What To Know About The Johnson & Johnson COVID Vaccine And Guillain-Barre Syndrome
The FDA added a warning on the J&J shot after some people developed a rare disorder. Here's why you shouldn't panic. (Source: Science - The Huffington Post)
Source: Science - The Huffington Post - July 12, 2021 Category: Science Source Type: news

J&J COVID vaccine may pose 'small possible risk' of rare neurological syndrome, CDC says
The U.S. Centers for Disease Control and Prevention said on Monday that it has received rare reports of Guillain-Barré syndrome among people who got Johnson & Johnson's Janssen shot. The vaccine has been approved in Canada but never used. (Source: CBC | Health)
Source: CBC | Health - July 12, 2021 Category: Consumer Health News Tags: News/Health Source Type: news

Johnson & Johnson Statement on COVID-19 Vaccine (7/12)
NEW BRUNSWICK, N.J., July 12, 2021 – The safety and well-being of the people who use our products is our number one priority. Rare cases of the neurological disorder, Guillain-Barré syndrome have been reported following vaccination with the Janssen COVID-19 vaccine. Most occurred within 42 days after vaccination. While the chance of having this occur is very low, Johnson & Johnson has updated its COVID-19 Vaccine Factsheet to include important information about these rare cases and on the signs and symptoms of Guillain-Barré syndrome. Updates with this new information will be implemented in other regions...
Source: Johnson and Johnson - July 12, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Case Reports Identify Guillain-Barr é Variants After COVID Vaccine Case Reports Identify Guillain-Barr é Variants After COVID Vaccine
Report findings from India and the UK'should prompt all physicians to be vigilant in recognizing Guillain-Barr é syndrome in patients who have received the AstraZeneca vaccine,'investigators say.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - July 1, 2021 Category: Infectious Diseases Tags: Neurology & Neurosurgery News Source Type: news

Seven Cases of Guillain-Barr é Noted After COVID-19 Vaccine in India
MONDAY, June 28, 2021 -- Cases of Guillain-Barr é syndrome (GBS) have been reported after receipt of the Oxford-AstraZeneca severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, according to two reports published online June 10 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 28, 2021 Category: Pharmaceuticals Source Type: news

Four men develop life-threatening condition after receiving AstraZeneca jab - symptoms
THE ASTRAZENECA vaccine is set to come under intense scrutiny once again after four British men developed a potentially life-threatening condition shortly after receiving the jab. The vaccine recipients developed Guillain-Barr é syndrome - a potentially deadly condition. What are the symptoms? (Source: Daily Express - Health)
Source: Daily Express - Health - June 22, 2021 Category: Consumer Health News Source Type: news

Four Brits develop Guillain-Barré syndrome just days after having AstraZeneca's Covid jab
Four cases of potentially deadly Guillain-Barré syndrome - in which the body's immune system breaks down - were recorded in Nottingham just 11 to 12 days after having the vaccine. (Source: the Mail online | Health)
Source: the Mail online | Health - June 22, 2021 Category: Consumer Health News Source Type: news

AstraZeneca Covid vaccine linked to rare neurological disorder in India, UK
In Guillain-Barre syndrome (GBS), the body's immune system mistakenly attacks part of its peripheral nervous system --the network of nerves located outside of the brain and spinal cord. (Source: The Economic Times)
Source: The Economic Times - June 22, 2021 Category: Consumer Health News Source Type: news

Rare neurological disorder documented following COVID-19 vaccination
(Wiley) In two separate articles in the Annals of Neurology, clinicians in India and England report cases of a rare neurological disorder called Guillain-Barre? syndrome after individuals were vaccinated against COVID-19. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 21, 2021 Category: International Medicine & Public Health Source Type: news

Covid symptoms: Signs in the feet to spot - from skin lesions to Guillain-Barre Syndrome
COVID symptoms are being widely investigated - how the virus affects all areas of the body. A new review paper has looked at the clinical manifestations of COVID-19 in the feet, finding vascular, dermatological and neurological symptoms have been reported. (Source: Daily Express - Health)
Source: Daily Express - Health - June 7, 2021 Category: Consumer Health News Source Type: news

AIDP or Guillain-barre Syndrome Associated With COVID-19 AIDP or Guillain-barre Syndrome Associated With COVID-19
Was this patient's Guillain-Barre Syndrome a sequela of COVID-19? This case highlights the need for physicians to be aware of this possible complication when evaluating COVID-19 patients.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 3, 2021 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news

Guillain-Barre Syndrome
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - May 20, 2021 Category: General Medicine Source Type: news

AstraZeneca vaccine reactions: Blood clots still 'very rare' – other side effects to note
THE ASTRAZENECA Covid vaccine is now under investigation from the European Medicines Agency . This follows recipients of the jab developing Guillain-Barre syndrome - another side effect connected to the vaccine. (Source: Daily Express - Health)
Source: Daily Express - Health - May 7, 2021 Category: Consumer Health News Source Type: news

COVID-19 Vaccine and Guillain-barre Syndrome COVID-19 Vaccine and Guillain-barre Syndrome
In this commentary, the authors warn against jumping to conclusions regarding an association of COVID-19 vaccines with Guillain-Barre syndrome, even if sporadic cases of GBS emerge.Brain (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - April 12, 2021 Category: Intensive Care Tags: Neurology & Neurosurgery Journal Article Source Type: news

No Proof COVID Vaccines Can Trigger Guillain-Barr é Syndrome
WEDNESDAY, April 7, 2021 -- Two people in the Johnson& Johnson COVID-19 vaccine trial developed Guillain-Barré syndrome, but it's highly doubtful the vaccine is to blame, according to a just-published case study. Although both people... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 7, 2021 Category: General Medicine Source Type: news

No Association Between COVID-19 and Guillain-Barré Syndrome
No abstract available (Source: Lippincott's Bone and Joint Newsletter)
Source: Lippincott's Bone and Joint Newsletter - March 28, 2021 Category: Orthopaedics Tags: Snapshot Source Type: news

Janssen Announces U.S. FDA Approval of CABENUVA (rilpivirine and cabotegravir), the First Long-Acting Regimen for the Treatment of HIV
TITUSVILLE, N.J., January 21, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved CABENUVA (consisting of Janssen’s rilpivirine and ViiV Healthcare’s cabotegravir), the first and only once-monthly, long-acting regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults. The novel regimen was co-developed as part of a collaboration with ViiV Healthcare and builds on Janssen’s 25-year commitment to make HIV history. In the U.S., ViiV Healthcare is the marketing authorization holde...
Source: Johnson and Johnson - January 22, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

No Causal Link Found for COVID-19, Guillain-Barr é Syndrome
MONDAY, Jan. 4, 2021 -- There seems to be no causal association between COVID-19 and Guillain-Barr é syndrome (GBS), according to a study published online Dec. 14 in Brain. Noting that reports of GBS have emerged during the pandemic, Stephen Keddie,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 4, 2021 Category: Pharmaceuticals Source Type: news

CDC Issues COVID-19 Vaccine Guidance for Underlying Conditions CDC Issues COVID-19 Vaccine Guidance for Underlying Conditions
The guidance had specific information for people with HIV, weakened immune systems, and autoimmune conditions such as Guillain-Barre syndrome and Bell's palsy who are planning to get the vaccine.WebMD Health News (Source: Medscape Pulmonary Medicine Headlines)
Source: Medscape Pulmonary Medicine Headlines - December 28, 2020 Category: Respiratory Medicine Tags: Infectious Diseases News Source Type: news

No Link Seen Between COVID, Guillain-Barr é Syndrome
Guillain-Barré syndrome is a rare autoimmune condition that attacks the peripheral nervous system, typically causing numbness, weakness and pain. In severe cases, it can cause paralysis and is sometimes fatal. (Source: WebMD Health)
Source: WebMD Health - December 18, 2020 Category: Consumer Health News Source Type: news

No Link Seen Between COVID, Guillain-Barr é Syndrome
FRIDAY, Dec. 18, 2020 -- There's no evidence of a link between COVID-19 and a serious neurological condition called Guillain-Barr é syndrome, British researchers say. Guillain-Barré syndrome is a rare autoimmune condition that attacks the... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 18, 2020 Category: General Medicine Source Type: news

No Link Seen Between COVID-19, Guillain-Barr é Syndrome
FRIDAY, Dec. 18, 2020 -- There's no evidence of a link between COVID-19 and a serious neurological condition called Guillain-Barré syndrome, British researchers say. Guillain-Barré syndrome is a rare autoimmune condition that attacks... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 18, 2020 Category: General Medicine Source Type: news

No association between COVID-19 and Guillain-Barr é syndrome
(University College London) Neuroscientists at UCL have found no significant association between COVID-19 and the potentially paralysing and sometimes fatal neurological condition Guillain-Barr é syndrome. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 13, 2020 Category: International Medicine & Public Health Source Type: news

Scientists Report First Case of Recurring Guillain-Barre Tied to COVID
THURSDAY, Dec. 10, 2020 -- The first known case of COVID-19 triggering a recurrence of Guillain-Barré syndrome has been reported by researchers. Guillain-Barré syndrome -- which can be sparked by viral and bacterial infections -- is a... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 10, 2020 Category: General Medicine Source Type: news

Fears coronavirus can trigger Guillain-Barre syndrome in sufferers
In April 2020, a man complaining of weakness in his face and limbs tested positive for COVID-19 and triggered Guillain-Barré Syndrome, a rare disorder that can lead to paralyzation. (Source: the Mail online | Health)
Source: the Mail online | Health - December 9, 2020 Category: Consumer Health News Source Type: news

Rutgers reports first instance of COVID-19 triggering recurrent Guillain-Barr é Syndrome
(Rutgers University) Researchers at Rutgers Robert Wood Johnson Medical School have reported the first instance of COVID-19 triggering a recurrence of Guillain-Barr é Syndrome - a rare disorder where the body's immune system attacks nerves and can lead to respiratory failure and death. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - December 8, 2020 Category: Infectious Diseases Source Type: news

When Symptoms of Covid-19 Don ’t Go Away
Research is underway to assess the pandemic ’s long-term effects and find ways to prevent and treat lasting symptoms. (Source: NYT Health)
Source: NYT Health - October 12, 2020 Category: Consumer Health News Authors: Jane E. Brody Tags: Coronavirus (2019-nCoV) SARS (Severe Acute Respiratory Syndrome) Lungs Heart Post-Traumatic Stress Disorder Guillain-Barre Syndrome Source Type: news

SIMPONI ARIA ® (golimumab) Approved by the U.S. Food and Drug Administration for Active Polyarticular Juvenile Idiopathic Arthritis and Extension of Its Active Psoriatic Arthritis Indication in Patients 2 Years of Age and Older
HORSHAM, PA, September 30, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA® (golimumab) for patients 2 years of age and older for the treatment of active pJIA and has extended the PsA indication for this same patient population. “This latest FDA approval of SIMPONI ARIA for pediatric use in active pJIA and active PsA not only brings a new option to young patients living with these diseases but also adds to the growing body of evidence for this treatment,” said Mathai Mammen, M.D., Ph.D., Glo...
Source: Johnson and Johnson - September 30, 2020 Category: Pharmaceuticals Source Type: news

Coronavirus-infected man, 57, is left paralysed after the disease triggers a rare condition
The Briton was rushed to A&E on April 13 after struggling to stand upright or move his arms, where a swab confirmed he was infected with Covid-19. He was diagnosed with Guillain-Barré syndrome. (Source: the Mail online | Health)
Source: the Mail online | Health - July 17, 2020 Category: Consumer Health News Source Type: news

Stanford biotech spinout snares $100M round on path toward IPO
Annexon Inc., a Stanford University spinout targeting a protein that could play a role in neurodegeneration and autoimmune and eye diseases, closed a $100 million round that may signal interest in an IPO. The South San Francisco company, led by President and CEO Ted Love, is looking to inhibit a pathway called complement. It has pushed two drugs into clinical trials and has raised more than $250 million. One drug, called ANX-005, is a monoclonal antibody in a Phase I/II study against Guillain-Barr é… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 2, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news

COVID-19 Update: Guillain-Barr é , States Quarantining Visitors COVID-19 Update: Guillain-Barr é , States Quarantining Visitors
These are the coronavirus stories you need to know about today.Medscape Medical News (Source: Medscape Emergency Medicine Headlines)
Source: Medscape Emergency Medicine Headlines - June 24, 2020 Category: Emergency Medicine Tags: Infectious Diseases News Source Type: news

First Reported US Case of Guillain-Barr é Linked to COVID-19 First Reported US Case of Guillain-Barr é Linked to COVID-19
A 54-year-old man from Pittsburgh is believed to represent the first documented US case of Guillain-Barre syndrome occurring soon after SARS-CoV-2 infection.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - June 24, 2020 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news